Stock Events

Stock Events

NuCana 

$1.4000
133
-$0.03-2.1% 20:00 Today
+$0.00+0%20:00After hours

Statistics

Day High
1.42
Day Low
1.3829
52W High
7.22
52W Low
1.21
Volume
32,169
Avg. Volume
66,247
Mkt Cap
5.83M
P/E Ratio
0.01
Dividend Yield
-
Dividend
-

Earnings

16MayExpected
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-12.18
-8.12
-4.06
0
Expected EPS
-3.49
Actual EPS
-3.25

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-40.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NCNA. It's not an investment recommendation.
NVIDIA
18
NVDA
Schwab US Dividend Equity
11
SCHD
YieldMax MSTR Option Income Strategy
11
MSTY
Tesla
10
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that develops medications in oncology, making it a direct competitor to NuCana's cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb operates in the same oncology and hematology space, competing with NuCana in the development of cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC focuses on the discovery and development of products in oncology, competing with NuCana in cancer drug development.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad portfolio that includes oncology, directly competing with NuCana's cancer treatment research and development.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is involved in the research and development of oncology drugs, making it a competitor in the cancer treatment market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in competition with NuCana in the cancer treatment sector.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG engages in the pharmaceuticals and diagnostics business in oncology, directly competing with NuCana's cancer therapies.
Novartis
NVS
Mkt Cap292.35B
Novartis AG operates in the development and marketing of healthcare products, including oncology, competing with NuCana in cancer treatment innovations.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. has a strong focus on oncology, making it a competitor in the development of cancer treatments similar to NuCana's focus.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is engaged in the discovery, development, and marketing of pharmaceutical products, including for cancer, competing with NuCana in the oncology space.

About

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
Show more...
CEO
Hugh Stephen Griffith
Employees
12
Country
United Kingdom
ISIN
US67022C3043
WKN
000A41DTP

Listings

MU
DE
N04A.MU
F
DE
N040.F
STU
DE
N040.STU
MU
DE
N040.MU

0 Comments

Share your thoughts

FAQ

What is NuCana stock price today?▼
The current price of NCNA is $1.40 USD — it has decreased by -2.1% in the past 24 hours. Watch NuCana stock price performance more closely on the chart.
What is NuCana stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange NuCana stocks are traded under the ticker NCNA.
Is NuCana stock price growing?▼
NCNA stock has fallen by -20.45% compared to the previous week, the month change is a +0.72% rise, over the last year NuCana has showed a -51.05% decrease.
What is NuCana market cap?▼
Today NuCana has the market capitalization of 5.83M
What were NuCana earnings last quarter?▼
NCNA earnings for the last quarter are -3.25 USD per share, whereas the estimation was -3.49 USD resulting in a +6.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NuCana revenue for the last year?▼
NuCana revenue for the last year amounts to 0 USD.
What is NuCana net income for the last year?▼
NCNA net income for the last year is -40.03M USD.
How many employees does NuCana have?▼
As of September 04, 2026, the company has 12 employees.
In which sector is NuCana located?▼
NuCana operates in the Health & Wellness sector.
When did NuCana complete a stock split?▼
The last stock split for NuCana was on August 11, 2025 with a ratio of 1:200.
Where is NuCana headquartered?▼
NuCana is headquartered in Edinburgh, United Kingdom.